サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1439278

関節内補充療法デバイス - 世界市場の考察、競合情勢、市場予測（2030年）

Viscosupplementation Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
関節内補充療法デバイス - 世界市場の考察、競合情勢、市場予測（2030年）
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2～10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の関節内補充療法デバイスの市場規模は、2023年に40億8,000万米ドル、2030年までに64億3,000万米ドルに達し、2024年～2030年の予測期間にCAGRで7.94％の成長が見込まれます。関節内補充療法デバイスに対する需要の高まりは主に、老年人口の増加と変形性関節症の有病率の上昇、非外科的治療に対する需要の高まり、ヒアルロン酸ベースの治療法の開発の進歩、関節内補充療法に対する明確な償還政策などに起因しています。

関節内補充療法の市場力学

世界保健機関（WHO）（2022）によると、2019年に世界で約5億2,800万人が変形性関節症に苦しんでいます。同じ資料によると、変形性関節症は1,900万年の障害生存年数（YLDs）に寄与しています。変形性関節症は「wear and tear」としても知られ、関節内の軟骨がすり減ることによって引き起こされる激痛、腫れなどの症状を伴います。

また、Australian Institute of Health and Welfare（2020）のレポートによると、2017年～2018年にオーストラリア国民の11人に1人が変形性関節症に罹患しており、その数は約220万人に上ります。

したがって、人々の間での変形性関節症の増加は、これらのデバイスが関節炎/変形性関節症関節（もっとも一般的には膝）の痛みや腫れを軽減するのに役立つため、世界の関節内補充療法デバイス市場を急成長させる可能性が高いです。

老年人口の増加は、関節内補充療法デバイス市場を加速させるもう1つの要因です。例えば、WHO（2022）によると、2030年までに世界全体で、6人のうち少なくとも1人が60歳以上になると予測されています。2050年までに、60歳以上の人口は約21億人に達します。American College of Rheumatology（2021）によると、変形性関節症は高齢者に多く、40歳以上の人がもっとも罹患しやすいです。

2019年4月、米国食品医薬品局（FDA）は、変形性関節症に伴う痛みを最長6ヶ月間緩和するヒアルロン酸ナトリウムをプレフィルドした単回使用シリンジ「TRILURON（TM）」の市販前承認をFidia Pharmaに与えました。このように、製品認可の拡大も世界の関節内補充療法市場を押し上げると予測されています。

しかし、ヒアルロン酸療法に関連する高いコストや関節内補充療法の効率性の欠如といった特定の要因が、関節内補充療法デバイス市場の成長に課題をもたらすと予測されています。

関節内補充療法デバイス市場のセグメント分析

関節内補充療法製品セグメントでは、単回注射が予測期間に最有力セグメントとして台頭すると予測されています。

これは、単回注射のビスコサプリ療法製品は比較的新しく、すでにある3～5回注射のビスコサプリ療法製品と比較して費用対効果も高いからです。例えば、調査研究によると、1回の安定化ヒアルロン酸注射で治療された患者は、標準的なヒアルロン酸を5回注射された患者と比較して、統計的に有意な改善が見られました。

また、膝OAの治療における単回注射製品の使用を支持する研究結果もあり、医療システムへの経済的影響も多少改善されることがわかっています。

さらに、先進の製品を開発し、市場での地位を維持するため、主要企業が製品ポートフォリオを改善するための投資を増やしていることも、関節内補充療法デバイス市場のセグメント成長の促進要因となっています。例えば2019年3月、Seikagakuはイタリアで変形性膝関節症治療用の関節内単回注射ビスコサプリメント「HyLink®」を発売しました。

したがって、上記の要因が単回注射ビスコサプリメントの需要を促進し、それによって2024年～2030年の予測期間に関節内補充療法デバイス市場の成長に寄与する可能性が高いです。

当レポートでは、世界の関節内補充療法デバイス市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 関節内補充療法デバイス市場レポートのイントロダクション

第2章 関節内補充療法デバイス市場のエグゼクティブサマリー

  • 調査範囲
  • 市場の概要
  • 競合の評価

第3章 規制分析

  • 米国
  • 欧州
  • 日本
  • 中国

第4章 関節内補充療法デバイス市場の主な要因の分析

  • 関節内補充療法デバイス市場の促進要因
    • 変形性関節症の有病率の上昇
    • 非外科的治療の需要の増加
    • ヒアルロン酸ベースの製品の進歩
    • 有利な償還
  • 関節内補充療法デバイス市場の抑制要因と課題
    • 関節内補充療法治療の高いコスト
    • デバイスの非効率性
  • 関節内補充療法デバイス市場の機会
    • 低所得地域における成長機会
    • 市場拡大に向けた企業の戦略的取り組み

第5章 関節内補充療法デバイスのポーターのファイブフォース分析

第6章 関節内補充療法デバイスの市場レイアウト

  • 製品タイプ別
    • 単回注射
    • 3回注射
    • 5回注射
  • エンドユーザー別
    • 病院
    • 整形外科クリニック
    • その他
  • 地域別
    • 北米の関節内補充療法デバイスの市場規模（2021年～2030年）
    • 欧州の関節内補充療法デバイスの市場規模（2021年～2030年）
    • アジア太平洋の関節内補充療法デバイスの市場規模（2021年～2030年）
    • その他の地域の関節内補充療法デバイスの市場規模（2021年～2030年）

第7章 関節内補充療法デバイスの企業と製品のプロファイル

  • Anika Therapeutics, Inc.
  • SEIKAGAKU CORPORATION
  • Sanofi
  • Zimmer Biomet
  • Smith & Nephew
  • Ferring B.V.
  • Lifecore Biomedical, LLC
  • LG Chem.
  • Fidia Farmaceutici S.p.A
  • OrthogenRx
  • Bioventus
  • DePuy Synthes (Johnson & Johnson)
  • APTISSEN
  • Vivacy
  • KiOmed Pharma
  • BioPolymer GmbH & Co KG
  • ALBOMED® GmbH

第8章 KOLの見解

第9章 プロジェクトのアプローチ

第10章 DelveInsightのサービス内容

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Viscosupplementation Devices Market in Global (2021-2030)
  • Table 3: Viscosupplementation Devices Market in Global by Product Type (2021-2030)
  • Table 4: Viscosupplementation Devices Market in Global by End-User (2021-2030)
  • Table 5: Viscosupplementation Devices Market in Global by Geography (2021-2030)
  • Table 6: Viscosupplementation Devices Market in North America (2021-2030)
  • Table 7: Viscosupplementation Devices Market in the US (2021-2030)
  • Table 8: Viscosupplementation Devices Market in Canada (2021-2030)
  • Table 9: Viscosupplementation Devices Market in Mexico (2021-2030)
  • Table 10: Viscosupplementation Devices Market in Europe (2021-2030)
  • Table 11: Viscosupplementation Devices Market in France (2021-2030)
  • Table 12: Viscosupplementation Devices Market in Germany (2021-2030)
  • Table 13: Viscosupplementation Devices Market in the United Kingdom (2021-2030)
  • Table 14: Viscosupplementation Devices Market in Italy (2021-2030)
  • Table 15: Viscosupplementation Devices Market in Spain (2021-2030)
  • Table 16: Viscosupplementation Devices Market in Rest of Europe (2021-2030)
  • Table 17: Viscosupplementation Devices Market in Asia-Pacific (2021-2030)
  • Table 18: Viscosupplementation Devices Market in China (2021-2030)
  • Table 19: Viscosupplementation Devices Market in Japan (2021-2030)
  • Table 20: Viscosupplementation Devices Market in India (2021-2030)
  • Table 21: Viscosupplementation Devices Market in Australia (2021-2030)
  • Table 22: Viscosupplementation Devices Market in South Korea (2021-2030)
  • Table 23: Viscosupplementation Devices Market in Rest of Asia-Pacific (2021-2030)
  • Table 24: Viscosupplementation Devices Market in the Rest of World (2021-2030)
  • Table 25: Viscosupplementation Devices Market in the Middle East (2021-2030)
  • Table 26: Viscosupplementation Devices Market in Africa (2021-2030)
  • Table 27: Viscosupplementation Devices Market in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Viscosupplementation Devices Market in Global (2021-2030)
  • Figure 3: Viscosupplementation Devices Market in Global by Product Type (2021-2030)
  • Figure 4: Viscosupplementation Devices Market in Global by End-User (2021-2030)
  • Figure 5: Viscosupplementation Devices Market in Global by Geography (2021-2030)
  • Figure 6: Viscosupplementation Devices Market in North America (2021-2030)
  • Figure 7: Viscosupplementation Devices Market in the US (2021-2030)
  • Figure 8: Viscosupplementation Devices Market in Canada (2021-2030)
  • Figure 9: Viscosupplementation Devices Market in Mexico (2021-2030)
  • Figure 10: Viscosupplementation Devices Market in Europe (2021-2030)
  • Figure 11: Viscosupplementation Devices Market in France (2021-2030)
  • Figure 12: Viscosupplementation Devices Market in Germany (2021-2030)
  • Figure 13: Viscosupplementation Devices Market in the United Kingdom (2021-2030)
  • Figure 14: Viscosupplementation Devices Market in Italy (2021-2030)
  • Figure 15: Viscosupplementation Devices Market in Spain (2021-2030)
  • Figure 16: Viscosupplementation Devices Market in Rest of Europe (2021-2030)
  • Figure 17: Viscosupplementation Devices Market in Asia-Pacific (2021-2030)
  • Figure 18: Viscosupplementation Devices Market in China (2021-2030)
  • Figure 19: Viscosupplementation Devices Market in Japan (2021-2030)
  • Figure 20: Viscosupplementation Devices Market in India (2021-2030)
  • Figure 21: Viscosupplementation Devices Market in Australia (2021-2030)
  • Figure 22: Viscosupplementation Devices Market in South Korea (2021-2030)
  • Figure 23: Viscosupplementation Devices Market in Rest of Asia-Pacific (2021-2030)
  • Figure 24: Viscosupplementation Devices Market in the Rest of the World (2021-2030)
  • Figure 25: Viscosupplementation Devices Market in the Middle East (2021-2030)
  • Figure 26: Viscosupplementation Devices Market in Africa (2021-2030)
  • Figure 27: Viscosupplementation Devices Market in South America (2021-2030)
  • Figure 28: Market Drivers
  • Figure 29: Market Barriers
  • Figure 30: Market Opportunities
  • Figure 31: PORTER's Five Force Analysis
目次
Product Code: DIMDCL0068

The viscosupplementation Devices Market By Product Type (Single Injection, Three Injections, and Five Injections), End-User (Hospitals, Orthopedic Clinics, and Others), and Geography is projected to grow at a static CAGR forecast till 2030 due to the growing prevalence of osteoarthritis across the globe and rising demand for non-surgical treatment options for osteoarthritis.

The global viscosupplementation devices market was valued at USD 4.08 billion in 2023, growing at a CAGR of 7.94% during the forecast period from 2024 to 2030, to reach USD 6.43 billion by 2030. The rise in demand for Viscosupplementation Devices is primarily attributed to the rising prevalence of osteoarthritis coupled with the growing old age population, growing demand for non-surgical treatment, increasing advancements in the development of hyaluronic acid-based therapies, and well-defined reimbursement policy for viscosupplements, among others.

Viscosupplementation Devices Market Dynamics:

According to the World Health Organization 2022, worldwide around 528 million people were suffering from osteoarthritis in 2019. As per the same source osteoarthritis contributed to 19 million years lived with disability (YLDs). Osteoarthritis also known as "wear and tear" disease is associated with symptoms such as extreme pain, swelling, and others caused by the wearing down of cartilage within the joints.

Moreover, according to the Australian Institute of Health and Welfare 2020 report, between the years 2017 to 2018, one in eleven Australians have osteoarthritis which makes approximately 2.2 million people in the nation.

Therefore, rising osteoarthritis among the population is likely to surge the global viscosupplementation devices market as these devices help reduce pain and swelling in the arthritic/osteoarthritic joint (most commonly, the knee).

The increasing geriatric population is another factor accelerating the market for viscosupplementation devices market. For instance, according to WHO 2022, it has been expected that, globally by 2030, out of 6 at least 1 person will have his/her age 60 years or above. As per the same source, by 2050, the number of people aged 60 years or above will reach around 2.1 billion. The fact mentioned by the American College of Rheumatology 2021, says that osteoarthritis commonly occurs in the old age population and people aged 40 or above are most likely to suffer from it.

In April 2019, the US Food & Drug Administration (FDA) granted Fidia Pharma premarket approval for TRILURON(TM), a single-use syringe, prefilled with sodium hyaluronate to provide relief to the pain associated with osteoarthritis for up to six months. Thus, growing product approvals is also projected to boost the global market for the viscosupplementation market.

However, certain factors such as the high cost associated with hyaluronic acid therapy and the lack of efficiency of the viscosupplementation devices are expected to pose a challenge to the viscosupplementation devices market growth.

Viscosupplementation Devices Market Segment Analysis:

Viscosupplementation Devices Market By Product Type (Single Injection, Three Injections, and Five Injections), End-User (Hospitals, Orthopaedic Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the viscosupplementation devices product segment, the single injection is expected to emerge as a foremost segment during the forecasted period.

This is because single injection viscosupplementation products are relatively newer and are also cost-effective in comparison to already existing 3-5 injection viscosupplementation products. For instance, as per research studies, a statistically significant improvement was observed for patients treated with a single stabilized hyaluronic acid injection versus those who received standard hyaluronic acid in five injections.

Also, the studies support the use of single injection products in the treatment of knee OA and found a slight improvement in the economic impact on the healthcare system.

Furthermore, rising investments by key players for improving the product portfolio to develop advanced products and to maintain market position is also a driving factor for the segmental growth of the viscosupplementation devices market. For instance, in March 2019, Seikagaku launched HyLink®, an intra-articular single-injection viscosupplement for the treatment of knee osteoarthritis in Italy.

Thus, the above-mentioned factors are likely to propel the demand for single injection viscosupplementation, thereby contributing to the growth of the viscosupplementation devices market during the forecast period from 2024-2030.

North America is expected to dominate the overall Viscosupplementation Devices Market:

Among all the regions, North America is estimated to account for the largest share of the viscosupplementation devices market in the year 2023. Owing to the significance of key growth factors such as the rising prevalence of osteoarthritis, the growing burden of the old age population, sophisticated healthcare infrastructure, the presence of key players in the market, and fast regulatory approval for new products, in the region, the market for viscosupplementation devices is expected to grow during the forecast period 2024-2030.

The increasing patient population suffering from osteoarthritis is the key factor accelerating the growth of the viscosupplementation devices market in the region. The data published by the Centers for Disease Control and Prevention (CDC) 2020 states that approximately 32.5 million US adults are suffering from osteoarthritis.

The growing burden of the geriatric population is further going to increase the demand for viscosupplementation devices in the region. According to the data provided by the World Bank 2022, about 17% of US citizens aged 65 and above in 2021. Also, according to CDC 2022, around 54.1 million US adults were aged 65 or older in 2019. As per the same source, it has been estimated that by 2060, this number will reach up to 94.7 million in the US. As per the Arthritis by the Numbers report published by the Arthritis Foundation 2019, the risk for knee osteoarthritis increases with age and the annual incidence of knee OA is highest between 55 and 64 years old.

Hence, the above-mentioned factors are going to increase the growth of the viscosupplementation devices market in the region.

Viscosupplementation Devices Market Key Players:

Some of the key market players operating in the viscosupplementation devices market include Anika Therapeutics, Inc., SEIKAGAKU CORPORATION, Sanofi, Zimmer Biomet, Smith & Nephew, Ferring B.V., Lifecore Biomedical, LLC, LG Chem, Fidia Farmaceutici S.p.A, OrthogenRx, Bioventus, DePuy Synthes (Johnson & Johnson), Vivacy, APTISSEN, KiOmed Pharma, BioPolymer GmbH & Co KG, ALBOMED® GmbH and others.

Recent Developmental Activities in the Viscosupplementation Devices Market:

In August 2022, Seikagaku announced the launch of HyLink®, an Intra-Articular Single Injection Viscosupplement for the treatment of knee osteoarthritis in Taiwan.

In January 2022, Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare commercially launched NeoVisc+ 2 mL and NeoVisc ONE 4 mL in Canada for the treatment and improvement of joint functionality and pain in patients suffering from degenerative or mechanical arthropathy of the knees.

Key Takeaway from the Viscosupplementation Devices Market Report Study

Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the Global Viscosupplementation Devices Market.

Various opportunities available for the other competitor in the Viscosupplementation Devices Market space.

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for Viscosupplementation Devices market growth in the coming future?

Target Audience who can be benefited from the Viscosupplementation Devices Market Report Study

Viscosupplementation Devices providers

Research organizations and consulting companies

Viscosupplementation Devices-related organization, association, forum, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders in viscosupplementation devices

Various End-users who want to know more about the viscosupplementation devices market and the latest technological developments in the viscosupplementation devices market.

Frequently Asked Questions for Viscosupplementation Devices Market:

1. What are viscosupplementation devices?

Viscosupplementation devices are preparations that have hyaluronic acid filled in an injection, which is administered into the knee joint to relieve pain associated with osteoarthritis.

2. What is the market for global viscosupplementation devices?

The global viscosupplementation devices market was valued at USD 4.08 billion in 2023, growing at a CAGR of 7.94% during the forecast period from 2024 to 2030, to reach USD 6.43 billion by 2030.

3. What are the drivers for the global viscosupplementation devices market?

The major factors driving the demand for viscosupplementation devices are the rising worldwide prevalence of musculoskeletal disorders such as osteoarthritis, the increasing old age population, recent product approvals, and growing demand for non-surgical osteoarthritis treatment, among others.

4. Who are the key players operating in global viscosupplementation devices?

Some of the key market players operating in the viscosupplementation devices market include Anika Therapeutics, Inc., SEIKAGAKU CORPORATION, Sanofi, Zimmer Biomet, Smith & Nephew, Ferring B.V., Lifecore Biomedical, LLC, LG Chem, Fidia Farmaceutici S.p.A, OrthogenRx, Bioventus, DePuy Synthes (Johnson & Johnson), Vivacy, APTISSEN, KiOmed Pharma, BioPolymer GmbH & Co KG, ALBOMED® GmbH, and others.

5. Which region has the highest share in the viscosupplementation devices market?

North America is expected to dominate the overall viscosupplementation devices market. This domination is due to the favorable reimbursement scenario, advanced healthcare infrastructure, and developed research & development facilities in the region.

Table of Contents

1. Viscosupplementation Devices Market Report Introduction

2. Viscosupplementation Devices Market Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment

3. Regulatory Analysis

  • 3.1. The United States
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Viscosupplementation Devices Market Key Factors Analysis

  • 4.1. Viscosupplementation Devices Market Drivers
    • 4.1.1. Rising prevalence of osteoarthritis
    • 4.1.2. Increase in demand for non-surgical treatment
    • 4.1.3. Rising advancement in hyaluronic acid-based products
    • 4.1.4. Favorable reimbursement
  • 4.2. Viscosupplementation Devices Market Restraints and Challenges
    • 4.2.1. High cost of the Viscosupplementation Treatment
    • 4.2.2. The inefficiency of the Device
  • 4.3. Viscosupplementation Devices Market Opportunities
    • 4.3.1. Growth opportunities in low-income regions
    • 4.3.2. Strategic initiatives by Companies for Market Expansion

5. Viscosupplementation Devices Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes 5.5 Competitive Rivalry

6. Viscosupplementation Devices Market Layout

  • 6.1. By Product Type
    • 6.1.1. Single Injection
    • 6.1.2. Three Injections
    • 6.1.3. Five Injections
  • 6.2. By End-User
    • 6.2.1. Hospitals
    • 6.2.2. Orthopedic Clinics
    • 6.2.3. Others
  • 6.3. By Geography
    • 6.3.1. North America Viscosupplementation Devices Market Size in USD million (2021-2030)
      • 6.3.1.1. United States Viscosupplementation Devices Market Size in USD million (2021-2030)
      • 6.3.1.2. Canada Viscosupplementation Devices Market Size in USD million (2021-2030)
      • 6.3.1.3. Mexico Viscosupplementation Devices Market Size in USD million (2021-2030)
    • 6.3.2. Europe Viscosupplementation Devices Market Size in USD million (2021-2030)
      • 6.3.2.1. France Viscosupplementation Devices Market Size in USD million (2021-2030)
      • 6.3.2.2. Germany Viscosupplementation Devices Market Size in USD million (2021-2030)
      • 6.3.2.3. United Kingdom Viscosupplementation Devices Market Size in USD million (2021-2030)
      • 6.3.2.4. Italy Viscosupplementation Devices Market Size in USD million (2021-2030)
      • 6.3.2.5. Spain Viscosupplementation Devices Market Size in USD million (2021-2030)
      • 6.3.2.6. Rest of Europe Viscosupplementation Devices Market Size in USD million (2021-2030)
    • 6.3.3. Asia-Pacific Viscosupplementation Devices Market Size in USD million (2021-2030)
      • 6.3.3.1. China Viscosupplementation Devices Market Size in USD million (2021-2030)
      • 6.3.3.2. Japan Viscosupplementation Devices Market Size in USD million (2021-2030)
      • 6.3.3.3. India Viscosupplementation Devices Market Size in USD million (2021-2030)
      • 6.3.3.4. Australia Viscosupplementation Devices Market Size in USD million (2021-2030)
      • 6.3.3.5. South Korea Viscosupplementation Devices Market Size in USD million (2021-2030)
      • 6.3.3.6. Rest of Asia Pacific Viscosupplementation Devices Market Size in USD million (2021-2030)
    • 6.3.4. Rest of the World (RoW) Viscosupplementation Devices Market Size in USD million (2021-2030)
      • 6.3.4.1. Middle East Viscosupplementation Devices Market Size in USD million (2021-2030)
      • 6.3.4.2. Africa Viscosupplementation Devices Market Size in USD million (2021-2030)
      • 6.3.4.3. South America Viscosupplementation Devices Market Size in USD million (2021-2030)

7. Viscosupplementation Devices Company and Product Profiles

  • 7.1. Anika Therapeutics, Inc.
    • 7.1.1. Company Overview
    • 7.1.2. Company Snapshot
    • 7.1.3. Financial Overview
    • 7.1.4. Product Listing
    • 7.1.5. Entropy
  • 7.2. SEIKAGAKU CORPORATION
    • 7.2.1. Company Overview
    • 7.2.2. Company Snapshot
    • 7.2.3. Financial Overview
    • 7.2.4. Product Listing
    • 7.2.5. Entropy
  • 7.3. Sanofi
    • 7.3.1. Company Overview
    • 7.3.2. Company Snapshot
    • 7.3.3. Financial Overview
    • 7.3.4. Product Listing
    • 7.3.5. Entropy
  • 7.4. Zimmer Biomet
    • 7.4.1. Company Overview
    • 7.4.2. Company Snapshot
    • 7.4.3. Financial Overview
    • 7.4.4. Product Listing
    • 7.4.5. Entropy
  • 7.5. Smith & Nephew
    • 7.5.1. Company Overview
    • 7.5.2. Company Snapshot
    • 7.5.3. Financial Overview
    • 7.5.4. Product Listing
    • 7.5.5. Entropy
  • 7.6. Ferring B.V.
    • 7.6.1. Company Overview
    • 7.6.2. Company Snapshot
    • 7.6.3. Financial Overview
    • 7.6.4. Product Listing
    • 7.6.5. Entropy
  • 7.7. Lifecore Biomedical, LLC
    • 7.7.1. Company Overview
    • 7.7.2. Company Snapshot
    • 7.7.3. Financial Overview
    • 7.7.4. Product Listing
    • 7.7.5. Entropy
  • 7.8. LG Chem.
    • 7.8.1. Company Overview
    • 7.8.2. Company Snapshot
    • 7.8.3. Financial Overview
    • 7.8.4. Product Listing
    • 7.8.5. Entropy
  • 7.9. Fidia Farmaceutici S.p.A
    • 7.9.1. Company Overview
    • 7.9.2. Company Snapshot
    • 7.9.3. Financial Overview
    • 7.9.4. Product Listing
    • 7.9.5. Entropy
  • 7.10. OrthogenRx
    • 7.10.1. Company Overview
    • 7.10.2. Company Snapshot
    • 7.10.3. Financial Overview
    • 7.10.4. Product Listing
    • 7.10.5. Entropy
  • 7.11. Bioventus
    • 7.11.1. Company Overview
    • 7.11.2. Company Snapshot
    • 7.11.3. Financial Overview
    • 7.11.4. Product Listing
    • 7.11.5. Entropy
  • 7.12. DePuy Synthes (Johnson & Johnson)
    • 7.12.1. Company Overview
    • 7.12.2. Company Snapshot
    • 7.12.3. Financial Overview
    • 7.12.4. Product Listing
    • 7.12.5. Entropy
  • 7.13. APTISSEN
    • 7.13.1. Company Overview
    • 7.13.2. Company Snapshot
    • 7.13.3. Financial Overview
    • 7.13.4. Product Listing
    • 7.13.5. Entropy
  • 7.14. Vivacy
    • 7.14.1. Company Overview
    • 7.14.2. Company Snapshot
    • 7.14.3. Financial Overview
    • 7.14.4. Product Listing
    • 7.14.5. Entropy
  • 7.15. KiOmed Pharma
    • 7.15.1. Company Overview
    • 7.15.2. Company Snapshot
    • 7.15.3. Financial Overview
    • 7.15.4. Product Listing
    • 7.15.5. Entropy
  • 7.16. BioPolymer GmbH & Co KG
    • 7.16.1. Company Overview
    • 7.16.2. Company Snapshot
    • 7.16.3. Financial Overview
    • 7.16.4. Product Listing
    • 7.16.5. Entropy
  • 7.17. ALBOMED® GmbH
    • 7.17.1. Company Overview
    • 7.17.2. Company Snapshot
    • 7.17.3. Financial Overview
    • 7.17.4. Product Listing
    • 7.17.5. Entropy

8. KOL Views

9. Project Approach

10. DelveInsight Capabilities

11. About DelveInsight

12. Disclaimer & Contact Us